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“The Arizona Department of Health Services initiated
the development of this 
plan with the intent to set
priorities by formulating
objectives and suggesting
strategies to address chronic
obstructive pulmonary 
disease as a serious public
health issue in Arizona.”
1Dear Arizona Residents:
Chronic Obstructive Lung Disease (COPD) is a major health problem in Arizona and is the third
leading cause of death in our state.  In the United States, COPD is ranked the fourth leading cause of
morbidity and mortality; the incidence of the disease is on the rise.
The Arizona Department of Health Services has developed the Arizona Comprehensive Lung
Disease Control Plan. This plan sets the priorities, objectives, and strategies to reduce deaths attributable
to COPD and to aid in reducing the adult population in Arizona who become disabled due to chronic
lung disease. In addition, the plan promotes improvements in the system of care for individuals
diagnosed with COPD, as well as promoting the prevention and early detection of lung disease.  
The risk factors for COPD include genetic, physical wellness, behavioral, and environmental
components: the greater being behavioral and environmental.  It is estimated that 80% to 90% of
COPD cases in the United States are attributable to tobacco smoking.  This presents a tremendous
challenge to the public health community in the areas of prevention and early detection given that
smoking abstinence can prevent the occurrence of COPD, and smoking cessation has a powerful
influence on determining the outcome for those who suffer from this disease.
The plan is designed to assist stakeholders, policymakers, health care professionals, educators, 
and public health workers in developing and coordinating approaches to address COPD among their
constituents.  The plan is an important step in raising awareness of the serious public health problem
of COPD, and it provides a framework for action to reduce the impact of lung disease in Arizona.
Sincerely,
Susan Gerard
Director
L e t t e r  F r o m  O u r  D i r e c t o r
Arizona Comprehensive Lung Disease Control Plan
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Chronic Obstructive Pulmonary Disease (COPD), also known as Chronic
Obstructive Lung Disease or Chronic Lower Respiratory Disease, is a
major public health problem.  It is projected to rank fifth in 2020 as a 
world-wide burden of disease
according to the World Bank/World
Health Organization.1 It is currently
the fourth leading cause of morbidity and mortality
in the United States,2 and in 2002, COPD was the
third leading cause of death in Arizona.3 COPD 
is also the only major disease that is rising in 
prevalence and mortality while all other major
causes of death are declining.4
Although COPD is such a significant cause of
mortality and morbidity worldwide, it has failed to
receive commensurate attention from the healthcare
community and government officials.  This can be
attributed to various factors.  There is incomplete
information about the causes and prevalence of
COPD.  Prevalence and mortality data greatly
underestimate the total burden of COPD because
the disease is usually not diagnosed until it is clini-
cally apparent and moderately advanced.5 Mortality
data also underestimate COPD as a cause of death
because the disease is more likely to be cited as an
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underlying cause of death, or may not be cited at
all, rather than being the attributed cause of death.6
COPD is not characterized by the drama that
surrounds sudden and life-threatening illness such
as heart attack and stroke, which has brought the
combined efforts of the public, governmental
agencies, and the medical community to devise
effective strategies for prevention and early
treatment for these chronic diseases.  By contrast,
COPD lacks compelling symptoms or may be
asymptomatic during years of progressive loss of
lung function on the pathway to disabling dyspnea
and premature mortality from acute and chronic
respiratory failure.7 One of the most frightening
aspects of this disease is the fact that many afflicted
with COPD do not realize they have it until they
have lost significant lung function, at which time
mundane activities such as walking short distances
can become difficult.  Often the symptoms of
COPD are attributed to a common cold, allergies,
E x e c u t i v e  S u m m a r y
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8lack of exercise, or aging and are therefore unrecog-
nized by patients or underdiagnosed by physicians.
According to the American Lung Association,
smoking causes 80 to 90% of COPD cases; and
smokers are 10 times more likely than nonsmokers
to die of the disease.8 The association of the disease
with smoking has also attributed to its lack of
importance, since until recently it was seen as a
self-inflicted consequence of a bad habit, rather
than the tragic outcome of an addiction.
There is also confusion around the term COPD
among patients and healthcare professionals, which
complicates epidemiologic studies of COPD.
Patients may be diagnosed with smoker’s lung,
emphysema, bronchitis, chronic bronchitis, chronic
obstructive bronchitis or obstructive lung disease
and not identify with the term COPD.  
Self-report of physician diagnosis is a poor
measure of COPD prevalence, as in reports of
impaired lung function from the National Health
and Nutrition Examination Survey (NHANES) III
which carefully defined “obstructive” but included
in the analysis those in whom the impairments may
not have been “chronic” (e.g. viral infection),
“pulmonary” (e.g. congestive heart failure), or
“disease” (e.g. normal subjects with outlier labora-
tory values).9
These factors have resulted in surprisingly little
being known about the disease beyond its clinical
nature.  Studies of the disease burden on COPD
patients are scarce, and the social and healthcare
costs of the disease have not been well quantified.
There are limited data about COPD symptoms and
severity, disability or activity limitations, lifestyle
impact, social and psychosocial consequences,
healthcare utilization and current patterns of
treatment.10
The Arizona Department of Health Services
initiated the development of this plan with the intent
to set priorities by formulating objectives and
suggesting strategies to address chronic obstructive
pulmonary disease as a serious public health issue
in Arizona.  This plan begins with a detailed
description of chronic obstructive lung disease
followed by a discussion of proposed objectives and
strategies.  The overriding goals of this plan are
those stated in the Healthy People 2010:  Objectives
for Improving Health.  It is important that a
comprehensive approach be taken in working
toward these ambitious goals in Arizona, involving
the collaboration of community stakeholders.
Reduce the proportion of adults in Arizona whose activity is limited due to 
chronic lung disease.
Reduce deaths from COPD among Arizona adults.
T A B L E 1 Overr id ing Goals
E x e c u t i v e  S u m m a r y
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Epidemiology and Research
1. Establish a surveillance system to accurately track the mortality and morbidity of
COPD in Arizona, and also measure the impact on the economy of the state.
2. Support research into COPD etiology and clinical management, as well as 
healthcare policies and outcomes particularly as the activities relate to state issues.  
Treatment and Management
3. Improve early detection and diagnosis of COPD.
4. Promote better care for patients with COPD in Arizona according to established
guidelines.
5. Educate healthcare providers to manage patients with COPD to increase longevity
and quality of life and reduce exacerbations of the disease.
6. Establish physician-patient partnerships through education and management.
7. Improve access to pulmonary rehabilitation programs for Arizonans with COPD in
order to prevent and forestall premature morbidity and mortality.
Patient Education and Quality of Life Issues
8. Improve self-management knowledge and behavior in people with COPD, their
families and other caregivers.
9. Provide social support for patients, families, and caregivers impacted by COPD.
Prevention
10. Promote healthy living practices, which provide the most effective method of
preventing COPD (tobacco abstinence, periodic health checks, avoidance of
unhealthy work environments).
11. Reduce exposure to environmental and occupational risk factors to prevent the 
onset and progression of COPD.
Disparity
12. Identify and eliminate disparities in COPD prevention, diagnosis, and management
throughout the state.
Collaborative Efforts
13. Foster communication, collaboration and networking opportunities among patients,
caregivers, healthcare professionals, public health officials and other stakeholders.
Advocacy
14. Advocate and support policies to reduce the prevalence of tobacco use and 
secondhand smoke exposure among Arizonans.
Public Awareness
15. Increase awareness of the medical community, public health officials and the general
public that COPD is a serious public health problem in Arizona.
T A B L E 2 Plan Object ives by Topic

Definition:
Chronic obstructive pulmonary disease
(COPD) is defined as a disease state character-
ized by the presence of airflow obstruction due to
chronic bronchitis or emphysema.  The airflow
obstruction is generally progressive, accompanied
by airway hyperreactivity, and may be partially
reversible.  In the past asthma was also classified as
COPD, however it has been determined that the
reversibility of asthma and the characteristic 
inflammation with participation of complex cellular
and chemical mediators distinguishes it from these
conditions and it has been separated.  However, the
obstruction in many patients with COPD may
include a significant reversible component and
some patients with asthma may go on to develop
irreversible airflow obstruction indistinguishable
from COPD.11
Chronic bronchitis is defined as the presence
of chronic productive cough for three months in
each of two successive years in a patient for whom
other causes of chronic cough have been excluded.12
I n t roduc t ion
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Chronic bronchitis is characterized by chronic
cough and sputum production, intermittent
wheezing with variable degrees of shortness of
breath on exertion, recurring and continuing for
months.  
Chronic bronchitis results from inflammation and
swelling of the cells, which line the bronchus.  This
inflammation causes the production of excessive
mucus.  Both the swelling and excess mucus
contribute to the narrowing of the bronchi, making
air exchange more difficult and increasing the risk
of lung infections.
In chronic bronchitis, the mucous glands in the
lungs become larger.  The airways become inflamed,
and the bronchial walls thicken.  These changes and
the loss of supporting alveolar (air space) attach-
ments limit airflow by allowing the airway walls to
deform and narrow the airway lumen (the inside of
the airway tube).
Emphysema is defined as abnormal permanent
enlargement of the airspaces distal to the terminal
bronchioles, accompanied by destruction of their
walls and without obvious fibrosis.  Destruction is
I n t r o d u c t i o n
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defined as lack of uniformity in the pattern of respi-
ratory airspace enlargement; the orderly appearance
of the acinus and its components is disturbed and
may be lost.13 It is an abnormal, permanent enlarge-
ment of the air spaces (alveoli) located at the end of
the breathing passages of the lungs (terminal bron-
chioles), accompanied by the damage to the walls
between the air spaces in the lungs.  This leaves less
surface area for the normal exchange of oxygen and
carbon dioxide.
Emphysema reduces the normal elasticity of the
lung that helps to hold the airways open.  As a
result, the lungs lose their elasticity and exhalation
becomes more and more difficult.  Air remains
trapped in the overinflated lungs.  Those with
emphysema experience progressive shortness of
breath on exertion, variable degrees of coughing
and wheezing, and irreversible airflow obstruction.
Burden of COPD in Arizona
According to the Arizona Department of Health
Services Public Health Prevention Services,
“Arizona Chronic Disease Surveillance Indicators
Report,” September 2004, chronic lower respiratory
disease (synonymous with chronic obstructive
pulmonary disease) was the third leading cause of
death in Arizona for 2002, and accounted for 6% of
all deaths.  Hospital discharge data for that year
reveals 13,638 hospitalizations for COPD, which is
a rate of 249.2 per 100,000 population.  Estimates
of prevalence derived from the National Health
Interview Survey (NHIS) conducted by the National
Center for Health Statistics, Centers for Disease
Control and Prevention in 2001 and based on
Department of Economic Security population
estimates for 2004 indicate that the total number of
Arizonans with COPD is 290,124.14 
Figure 1 and Figure 2 from the Arizona Health
Status and Vital Statistics Report of 2003 illustrates
the burden of COPD (referred to as chronic lower
respiratory diseases) in Arizona:15
Figure 2 illustrates the burden as distributed
among racial and ethnic groups in Arizona.16
The number of deaths in Arizona from chronic
lower respiratory diseases by county is illustrated in
Figure 3.17
There are significant problems in the accuracy
of this data.  Reporting on cause of death often will
not indicate COPD as a cause of death, since it may
be seen only as a contributing factor to death due to
cardiopulmonary failure, pneumonia, or influenza,
or it may not be listed at all.  The same is true with
hospitalization data, which in addition does not
include emergency department or urgent care visits,
nor does it include those Arizona residents receiving
care in any Federal facility.
The NHIS data is dependent on the patient 
self-identifying that they have been diagnosed with
either chronic bronchitis or emphysema.  The
question regarding emphysema asks whether the
individual had “ever” been told by a doctor or other
I n t r o d u c t i o n
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F I G U R E 1 Twelve Leading Causes of  Death Among Ar izona Residents in  2003
1. Diseases of heart
2. Malignant neoplasms
3. Chronic lower
respiratory diseases
4. Accidents
(unintentional injuries)
5. Cerebrovascular
disease
6. Alzheimer’s disease
7. Influenza and pneumonia
8. Diabetes mellitus
9. Intentional self-harm
(suicide)
10. Chronic liver
disease and cirrhosis
11. Nephritis, nephrotic
syndrome and nephrosis
12. Assault (homicide)
10,649
9,451
2,522
2,466
2,356
1,691
1,248
1,124
807
625
550
480
0 2,500 5,000
BASED ON THE NUMBER OF DEATHS:
7,500 10,000 12,500
1. Diseases of heart
2. Malignant neoplasms
3. Chronic lower
respiratory diseases
4. Accidents
(unintentional injuries)
5. Cerebrovascular
disease
6. Alzheimer’s disease
7. Influenza and pneumonia
8. Diabetes mellitus
9. Intentional self-harm
(suicide)
10. Chronic liver
disease and cirrhosis
11. Nephritis, nephrotic
syndrome and nephrosis
12. Assault (homicide)
197.1
169.4
45.4
44.8
43.9
32.5
23.4
20.3
14.6
11.5
10.1
8.3
0.0 50.0 100.0
BASED ON AGE-ADJUSTED* MORTALITY RATES:
150.0 200.0 250.0
*Number of deaths per 100,000 population age-adjusted to the 2000 U.S. standard.
Note: the cause-of-death titles are according to the Tenth Revision of the International Classification of Diseases (ICD-10)
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health professional that they had the condition.  The
chronic bronchitis question asks if they had been
told by a doctor or health professional if they have
had the condition in the past 12 months.  As we see
from the American Thoracic Society (ATS) defini-
tion of chronic bronchitis, it is diagnosed over two
successive years, so a “yes” answer may represent
confusion with a viral bronchial illness.
Unfortunately, since diagnosis of COPD usually
takes place when it is well advanced due to late
onset of symptoms, these self-reported numbers
tend to be significantly lower than actual incidence.
Because of the limited data currently available
for social and economic impact of COPD in
Arizona, these indicators will be addressed on a
national level.
Burden of COPD in the
United States
COPD is a major cause of morbidity and
mortality in the United States.  An estimated 11.2
million adults have ever reported a physician
diagnosis of COPD.  A recent survey found that 24
million U.S. adults have some evidence of impaired
lung function, indicating under diagnosis of COPD.
The economic toll on the U.S. is quite heavy.
According to estimates made by the National Heart
Lung and Blood Institute in 2004, the annual cost to
the nation for COPD was $37.2 billion, including
$20.9 billion in direct healthcare expenditures, $7.4
billion in indirect morbidity costs, and $8.9 billion
in indirect mortality costs.18 In 2000, COPD was
responsible for 8 million physician office and
hospital outpatient visits, and 726,000 hospitaliza-
tions in the U.S.  
F I G U R E 2 Age-Adjusted Mortal i ty Rates for Chronic LowerRespiratory Diseases by Race/Ethnic Group, Arizona,  2003
White (non Hispanic)
ALL ARIZONANS
Black
Hispanic
American Indian
Asian
48.3
45.4
30.3
28.7
19.4
15.5
0.0 15.0
Number of deaths per 100,000 population
age-adjusted to the 2000 U.S. standard
30.0 45.0 60.0
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Mohave
57.5
Coconino
53.3
Navajo
36.6
La Paz
31.5
Yuma
35.3
31.5-37.5
NUMBER OF DEATHS PER 100,000 POPULATION
(age-adjusted to 2000 standard)
ARIZONA RATE = 45.4                            
37.6-47.8
47.9-68.6
Yavapai
42.9
Maricopa
43.8
Pima
47.0
45.0
Santa Cruz
Cochise
50.6
Graham
47.8
G
re
en
le
e
37
.5
Gila
68.6
Pinal
51.7
Apache
32.8
F I G U R E 3 Deaths from Chronic Lower Respiratory Diseases By County of  Residence,  Ar izona,  2003
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The impact of COPD to the working population
is underestimated, due to the assumption that it is a
disease of the elderly.  According to Centers for
Disease Control data published in 2002, 70% of
COPD patients were below the age of 65.19 The
disability caused by COPD is significant and is
documented in a survey released by the American
Lung Association in 2001, “Confronting C.O.P.D. in
America.”  It revealed that 51% of COPD patients
say their condition limits their ability to work, limits
them in normal physical exertion (70%), household
chores (56%), social activities (53%), sleeping
(50%) and family activities (46%).20
Beyond the debilitation of the patient, the
burden on the families of COPD patients is tremen-
dous, particularly in the later stages of the disease,
when mild exertion is difficult and the patient
ceases to be ambulatory.  This leads to more lost
wages, and numerous lifestyle accommodations
required on the part of the caregivers.  The burden
of COPD in the United States appears to be
generally increasing across many demographic
groups.  Data is limited since it is self-reported, and
does not include the large number of undiagnosed
cases of COPD, or hospitalizations where COPD is
not listed as the admitting diagnosis.
Risk Factors for COPD
Tobacco Use
The primary risk factor for COPD is tobacco
smoking, which accounts for an estimated 80 to
90% of the deaths caused by COPD.  Male smokers
are nearly 12 times as likely to die from COPD and
female smokers 13 times as likely to die as the
nonsmoking population.21 Smokers have higher
death rates for chronic bronchitis and emphysema,
as well as a higher prevalence of lung function
abnormalities, respiratory symptoms, and all forms
of chronic obstructive airway disease.  Differences
between smokers and nonsmokers increase in direct
proportion to quantity of smoking.  Age of starting,
total pack-years, and current smoking status are
predictive of COPD mortality.  Approximately 15%
of smokers develop clinically significant COPD.22
Also significant in terms of risk for COPD and
tobacco use is the finding that smoking during
pregnancy is associated with low birth weight, and
infants with low birth weight appear to have a
greater risk of developing COPD.23
Tobacco smoking is not the only cause of
COPD, and in some parts of the world it may not
even be the major cause due to the role of indoor air
pollution and occupational exposure.  The
prevailing notion that COPD is largely self-inflicted
is counterproductive for future research and disease
interventions.  It is crucial to take into account the
fact that not all smokers develop clinically signifi-
cant COPD.  This points to additional factors that
determine each individual’s susceptibility.
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Secondhand Smoke 
Smoking and probably passive smoke exposure
in childhood compromises lung growth leading to
diminished maximal lung function in young
adulthood.  These deficiencies may portend airway
hyperreactivity in adult life.  Passive smoke
exposure is a risk factor for symptoms of cough and
sputum production, and may account for some of
the COPD that develops in nonsmokers.24 The
World Health Organization (WHO) estimates that
passive smoking is associated with a 10 to 43%
increase in the risk of COPD in adults.
Ambient Air Pollution
The role of outdoor air pollution in causing
COPD is unclear, and the relative effect of short-
term, high peak exposures and long-term, low-level
exposures is yet to be resolved.  There is some
evidence that particles found in polluted air will
increase the total burden of inhaled particles, which
may contribute to total risk.  There are studies that
have shown comparative increases in chronic 
respiratory symptoms and pulmonary function
abnormalities among subjects living in communities
with significant outdoor air pollution.
Indoor air pollution from biomass fuel has been
established as a risk for the development of COPD.
This exposure is seen in environments where
biomass fuel is used for cooking and heating in
poorly vented dwellings, resulting in high levels of
indoor particulate matter.25
Occupational Inhalants  
The impact of occupational exposures in the
development of COPD is not yet fully known.
However, it has been established that occupational
exposures to dust, chemicals and some vapors,
irritants and fumes are important contributors, 
especially when the exposures are sufficiently
intense or prolonged.  Miners, firefighters, metal
workers, grain handlers, cotton workers, paper mill
workers, agricultural workers, construction workers,
and others employed in occupations associated with
prolonged exposure to dusts, fumes, or gases have
been seen to develop significant airflow obstruction,
reduced lung function and respiratory symptoms.26
A study of 3,380 British coal miners showed 
that there was clinically significant respiratory
dysfunction due to inhalation of coal dust, leading to
COPD, which was independent of the contribution
of smoking to incidence of disease among the
subjects.27 Grain dust exposure has also been 
determined to be a risk for both smokers and
nonsmokers.28
These occupational exposures can cause COPD
independently of tobacco smoking and increase the
risk in the presence of concurrent tobacco smoking
by increasing airway hyperresponsiveness.  A recent
study found that in the United States, 19% of
COPD overall could be attributed to occupational
hazard with 31% of COPD cases among never
smokers being work related.29
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Alpha1-antitrypsin Deficiency (AAT) 
This is the only genetic abnormality that is
known to lead to COPD.  Severe AAT deficiency
leads to premature emphysema, often with chronic
bronchitis and occasionally with bronchiectasis.  It
is estimated that this condition is responsible for
less than 5% of the emphysema cases in the U.S..
Alpha-1 related emphysema is caused by an
inherited lack of a protective protein called alpha-1
antitrypsin (AAT).  In normal and healthy individ-
uals, AAT protects the lungs from a natural enzyme
called neutrophil elastase.  Neutrophil elastase is an
enzyme that normally serves a useful purpose in
lung tissue – it digests damaged or aging cells and
bacteria in order to provide for healing.  However,
once it is done digesting those proteins, it does not
stop, and attacks the lung tissue.  Alpha-1-antitrypsin,
in sufficient amounts, will trap and destroy the
neutrophil elastase before it has a chance to begin
damaging the delicate lung tissue.  If allowed to
progress, this form of emphysema becomes 
chronic and lung tissue continues to be destroyed;
eventually it is fatal if the progress is not slowed
down or halted. 
It is estimated that there are 100,000 Americans
today who were born with Alpha-1 deficiency.
Alpha-1 related emphysema might afflict a majority
of these individuals.  However, AAT deficiency is
often under diagnosed or misdiagnosed.  As many
as 3% of individuals with chronic obstructive
pulmonary disease (COPD) may have undiagnosed
Alpha-1 deficiency.  Worldwide, it is estimated that
116 million people (25 million Americans) are
carriers of the disease.  WHO recommends that all
individuals with COPD, and adults and adolescents
with asthma (an estimated 20 million Americans) be
tested for Alpha-1.  A simple blood test can
determine whether a person has low levels of the
protective protein AAT.  Also, a DNA-based cheek
swab test has been recently developed to aid in
diagnosis.
The onset of Alpha-1 related emphysema
symptoms often appear between ages 32 and 41
years but may appear later.  The early age at which
the disease is present and the fact that the disease
most frequently appears in the lower, rather than the
upper, lung regions helps distinguish Alpha-1-related
emphysema from other types of emphysema.
Evidence shows that smoking significantly
increases the risk and severity of emphysema in
AAT deficient individuals and may decrease their
life span by as much as 10 years.30
Hyperresponsive Airways (Asthma) 
Asthma, nonspecific airway hyperresponsive-
ness and atopy (the genetic tendency to develop the
classic allergic diseases – atopic dermatitis, allergic
rhinitis or hay fever, and asthma) may possibly play
a role in COPD.  This relationship was originally
proposed in 1960 by Orie and colleagues who were
in the Netherlands, and thereby given the name “the
Dutch hypothesis.”31 Evidence is steadily accumu-
lating that this hyperresponsiveness is predictive of
an accelerated rate of decline of lung function in
smokers.  How these trends are related to the 
I n t r o d u c t i o n
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development of COPD is still unknown.  Airway
hyperresponsiveness may also develop after
exposure to tobacco smoke or other environmental
insults and thus may be a result of smoking-related
airway disease.
Infections 
There is an association of severe childhood
infections with reduced lung function and increased
respiratory symptoms in adulthood.  This may be
explained by an increased diagnosis of severe 
infections among children with underlying airway
hyperresponsiveness, which as discussed above may
itself be a risk factor.  Also, viral infections may be
related to another risk factor such as birth weight.
The rate of infections in childhood is also directly
related to the amount of exposure to secondhand
smoke.  Among adults, it has been established that
HIV infection accelerates the onset of smoking-
induced emphysema.32
Demographic Status 
Sex:  Although the rates of COPD deaths have
historically been higher in males than females,
beginning in 2000, women in the United States have
exceeded men in the number of deaths attributed to
COPD.  In 2002, over 61,000 females died
compared to 59,000 males.33 This has been 
attributed to the increasing use of tobacco among
females, and some studies have suggested that
women are more susceptible than men to the effects
of tobacco smoke.34
Race:  COPD is, as of now, the only lung
disease in which the white population has higher
age-adjusted death rates than blacks.  In 2002, the
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age-adjusted death rate in whites (44 per 100,000)
was 1.6 times greater than the rate in blacks (28 per
100,000).  The highest prevalence rates were in the
over age 65 population for whites, and in the 45 to
64 year old age group for blacks.  Black women had
the lowest age-adjusted death rates with 19 per
100,000.  Hispanics (male and female aggregated)
had an age-adjusted mortality rate of 19 per
100,000, which is markedly lower than the other
ethnic groups.35
Socioeconomic Status:  There is evidence that
the risk of developing COPD is inversely related to
socioeconomic status.  One correlation that has
been documented is the relationship to malnutrition.
Because lower serum levels of the major antioxidant
vitamins exist, the development of COPD may be
more prevalent among those who do not have
proper nutrition available.  Oxidant injury is
believed to be one of the mechanisms of alveolar
and airway damage, so a diet deficient in antioxi-
dants could be a risk factor.  There is also an 
association with reduced food intake and levels of
antioxidant vitamins in smokers as compared with
nonsmokers linking the risk of smoking and COPD.
Prevalence rates of tobacco use are also indirectly
related to socioeconomic status throughout the
world, as is the incidence of exposure to other
inhaled pollutants such as biomass fuels.36 The 
relationship between social position and respiratory
mortality may also be attributed to housing 
conditions, exposure to occupational pollutants, 
and childhood exposure to indoor air pollution.
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According to the U.S. Department of Health and
Human Services, National Health Interview Survey
of 2002, Table 3 substantiates the link between
socioeconomic status and the incidence of COPD.
Diagnosis and Staging
Diagnosis of COPD should be considered in any
patient who has any combination of the following:
• symptoms of cough 
• sputum production 
• dyspnea 
• history of exposure to risk factors for the disease
(especially smoking). 
The diagnosis requires spirometry (a test of
pulmonary function); post-bronchodilator (after the
administration of an inhaled bronchodilator)
FEV1/FVC <0.7 (a value comprised of the ratio of
the forced expiratory volume in one second of expi-
ration over the forced vital capacity) confirms the
presence of airflow limitation that is not fully
reversible.
Spirometry should be obtained in all persons
with the following history:
• exposure to cigarettes and/or environmental or
occupational pollutants 
Characteristic Emphysema Chronic Bronchitis
Education:
Less than H.S. diploma 3.5 (0.29) 6.3 (0.47)
H.S. diploma or G.E.D. 1.8 (0.16) 5.4 (0.29)
Some College 1.5 (0.16) 5.1 (0.28)
Bachelor’s degree or higher 0.8 (0.13) 2.7 (0.23)
Family Income:
Less than $20,000 3.1 (0.23) 6.9 (0.47)
$20,000-$34,999 1.7 (0.22) 5.6 (0.40)
$35,000-$54,999 1.5 (0.21) 4.4 (0.34)
$55,000-$74,999 1.2 (0.26) 4.9 (0.58)
$75,000 or more 0.7 (0.23) 2.9 (0.35)
Poverty Status:
Poor 3.5 (0.36) 8.3 (0.64)
Near Poor 2.4 (0.25) 5.9 (0.41)
Not Poor 1.2 (0.10) 4.0 (0.18)
T A B L E 3
Age-adjusted percents (with standard errors) 
of selected respiratory diseases among persons 
18 years of age and over.37
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• family history of chronic respiratory illness 
• presence of cough, sputum production or dyspnea. 
Spirometric Classification
Spirometric classification has proved useful in
predicting health status, utilization of healthcare
resources, and development of exacerbation and
mortality in COPD.  It is intended to be applicable
to populations and not to substitute clinical
judgment in the evaluation of the severity of disease
in individual patients.38
Spirometry is as important for the diagnosis of
COPD as blood pressure measurements are for the
diagnosis of hypertension. Testing with spirometry
determines the presence and severity of the airway
obstruction in COPD, by measuring how effectively,
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and how quickly, the lungs can be emptied.  It is
easy to administer, takes only a few minutes to
complete, and is noninvasive.  It can be conducted
in the primary care physicians’ office with a
spirometer, a relatively inexpensive device.  Patients
take a deep breath and exhale into the spirometer as
hard and fast as they can for a minimum of six
seconds.  The spirometer is connected to a computer
that records the volume of air exhaled in one second
(FEV1) and the total amount of air exhaled in a
forced maneuver (FVC).  The FEV1/FVC ratio is
the primary measurement in identifying an 
obstructive impairment of the airways, and is also
used to monitor the progression of COPD.39
It is accepted that a single measurement of
FEV1 incompletely represents the complex clinical
consequences of COPD because: 1) many patients
T A B L E 4 Spirometric general classification
Severity Postbronchodilator FEV1/FVC FEV1 % predicted
At risk >0.7 ≥ 80
Patients who:
smoke or have exposure to pollutants 
have cough, sputum or dyspnea 
have family history of respiratory disease 
Mild COPD ≤0.7 ≥ 80
Moderate COPD ≤0.7 50-80
Severe COPD ≤0.7 30-50
Very severe COPD ≤0.7 <30
FEV1: forced expiratory volume in one second; FVC: forced vital capacity.
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are practically asymptomatic; 2) persistent cough
and sputum production often precede the develop-
ment of airflow limitation and, in others, the first
symptom may be the development of dyspnea with
previously tolerated activities; and 3) in the clinical
course of the disease, systemic consequences, such
as weight loss and peripheral muscle wasting and
dysfunction, may develop.
Due to these and other factors, a staging system
that could offer a composite picture of disease
severity is highly desirable, although it is currently
unavailable.  However, spirometric classification is
useful in predicting outcomes such as health status
and mortality, and should be evaluated.
In addition to the FEV1, the Body Mass Index
(BMI) and level of dyspnea have proved useful in
predicting outcomes such as survival and it is
recommended that they be evaluated in all patients. 
BMI is easily obtained by dividing the weight
(in kg) over the height (in m2).  Values <21 kg/m-2
are associated with increased mortality.
Functional dyspnea can be assessed by the
Medical Research Council dyspnea scale:
0:  not troubled with breathlessness except with
strenuous exercise.
1: troubled by shortness of breath when hurrying or
walking up a slight hill.
2:  walks slower than people of the same age due to
breathlessness or has to stop for breath when
walking at own pace on the level.
3:  stops for breath after walking ~ 100m or after a
few minutes on the level.
4:  too breathless to leave the house or breathless
when dressing or undressing.40
Treatment/Management 
An effective treatment program for COPD
includes these four components of care:  (1) assess
and monitor disease, (2) reduce risk factors, (3)
manage stable COPD by both pharmacologic and
non-pharmacologic interventions, and (4) manage
acute exacerbations.  Spirometry is a key tool in the
assessment and monitoring of disease as is contin-
uous appraisal by healthcare providers of patients’
symptoms and health status.  The other three
components are addressed in the following sections.
Tobacco Smoking Cessation
Since smoking is the predominant risk factor for
COPD, and the majority of patients are smokers
when they are diagnosed, the first line of treatment
for the disease is smoking cessation.  Cessation of
smoking is the single most effective and cost
effective intervention to retard the progression of
COPD, and improve the quality of life and activity
level of the patient.  
Cigarette smoking is an addiction and a chronic
relapsing disorder regarded as a primary disorder by
the United States Department of Health and Human
Services Guidelines and by the WHO.  Therefore,
treating tobacco use and dependence should be
regarded as a primary and specific intervention.
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Preventing the development and progression of
COPD can be regarded as one of the secondary
effects prevented by treating the primary disorder,
because although cigarette smoking is the single
most important cause of COPD, it is also a major
risk factor for many other diseases including 
atherosclerotic vascular disease, cancer, peptic ulcer
and osteoporosis.
Smokers experience an accelerated rate of
decline in lung function.  Individual susceptibility,
however, varies greatly and depends on a complex
interaction of many genetic and environmental
factors.  It is often stated that 15% of smokers will
develop COPD.  This dramatically underestimates
the impact of smoking because the majority of
smokers will develop loss of lung function, and
reduced lung function, at any level, is predictive of
increased mortality.
Many smokers with undiagnosed COPD have
symptoms.  It is necessary to identify and properly
diagnose individuals earlier in the course of the
disease when physiological limitation and
symptoms are milder. Quitting smoking can slow
the progressive loss of lung function and can reduce
symptoms at any point in time. Yet, the beneficial
impact of smoking cessation on the natural history
of COPD is greatest the earlier cessation is
achieved.  Adolescents who quit smoking will have
increased lung growth.41
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Pharmacologic Interventions
Effective medications for COPD are available
and all patients who are symptomatic merit a trial of
drug treatment.  Therapy with currently available
medications can reduce or abolish symptoms,
increase exercise capacity, reduce the number and
severity of exacerbations, and improve health status.
Unfortunately, at present no drug treatment has
been shown to modify the rate of decline of lung
function.
The inhaled route is preferred when both inhaled
and oral formulations are available.  Smaller doses
of active treatment can be delivered directly with
equal or greater efficacy and with fewer side effects
when administered by inhalation. 
Patients must be educated in the correct use of
whatever inhalation device is employed.  Significant
numbers of patients cannot effectively coordinate
their breathing with a metered dose inhaler (MDI)
but can use a breath-activated inhaler, a dry powder
inhaler (DPI) device or a spacer chamber.  The latter
may be useful when inhaled corticosteroids are
administered, as it reduces the oropharyngeal 
deposition and subsequent local side effects 
associated with these drugs. 
Medications of different classes have been found
to be useful in treating COPD and can be used in
combination.  The overall approach to managing
stable COPD involves a stepwise increase in
treatment, depending on the severity of the disease.
Bronchodilators are a class of medications that
relax the muscles around the bronchi to allow easier
breathing.  They are typically indicated for the relief
28
of bronchospasm, which are contractions of the
smooth muscle in the walls of the bronchi and bron-
chioles that cause the airways to constrict or narrow.
Anticholinergic bronchodilators fall into this class
of COPD medications, as do short-acting beta2-
agonists, long-acting beta2-agonists, methylxan-
thines (e.g., theophylline), and a combination of an
anticholinergic bronchodilator and a short-acting
beta2-agonist. 
All major guidelines for COPD management
recommend beginning treatment with aerosol bron-
chodilators, which are inhaled directly into the
lungs and have few side effects.
In response to irritants such as cigarette smoke,
the body produces a chemical “messenger” called
acetylcholine that induces the airways to constrict.
Anticholinergic bronchodilators are the only
medications that act by blocking acetylcholine,
thereby relaxing the muscle tissue and keeping the
airways open.  Anticholinergic medications work via
part of the parasympathetic nervous system, which
controls airway size.  In addition to helping COPD
patients take fuller breaths, maintenance use of anti-
cholinergic medication may also help lower the
incidence of acute exacerbations in COPD patients.
Anticholinergics are most often administered
through metered-dose inhalers, or “puffers,” as they
are commonly called.  The effects of the medication
generally last from four to six hours, so physicians
typically prescribe use four times a day.  Inhaled
anticholinergics are minimally absorbed, resulting in
relatively few side effects.  Some common side
effects of ipratropium bromide, an inhaled anti-
cholinergic therapy, include cough and nervousness.
Anticholinergic bronchodilators, as a class, are
the number one prescribed bronchodilator used in
the treatment of COPD.  Currently, the leading anti-
cholinergic medication prescribed by physicians is
ipratropium bromide.  It is sold alone under the
brand name ATROVENT, Inhalation Aerosol or in
combination with albuterol sulfate under the brand
name COMBIVENT, Inhalation Aerosol. 
Beta2-agonists work via part of the nervous
system that controls muscle tissue around the
airways.  They work by stimulating receptors in the
sympathetic nervous system, leading to dilation of
air passages.  Two types of beta2-agonists are
available: short-acting beta-agonists and long-
acting beta-agonists. 
Short-acting beta2-agonists are recommended
for patients with COPD who experience intermittent
symptoms.  They are also used as a “rescue”
medication to fend off an impending attack of
shortness of breath.  Short-acting beta2-agonists are
typically prescribed along with anticholinergics to
open up the airways of COPD patients with contin-
uing symptoms.  The short-acting beta2-agonist
most commonly prescribed by physicians is
albuterol.  In clinical studies, the most common 
side effects of albuterol included tremor, nausea,
tachycardia, palpitations and nervousness.
Long-acting beta-agonists are bronchodilators
that are taken twice a day and, like short-acting
beta-agonists, work via part of the nervous system
that controls muscle tissue around the airways. 
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Long-acting beta-agonists are often prescribed
for nighttime breathing problems because they
provide up to 12 hours of relief.  Patients using 
long-acting beta-agonists need to be reminded to
continue using their short-acting beta-agonist for
“rescue” therapy, because long-acting beta-agonists
do not work as quickly and are indicated for use only
twice a day.  The most common side effects seen with
use of long-acting beta-agonists by patients with
COPD include headache, upper respiratory tract
infection, nasopharyngitis and cough.
Combination bronchodilators are the combina-
tion of an anticholinergic and short-acting 
beta2-agonist, and work via the part of the nervous
system that controls airway size, as well as the part
that controls muscle tissue around the airways.
Increased efficacy is seen with this combination
agent over the individual components, without an
increase in side effects.  The most common side
effects include bronchitis, upper respiratory tract
infection and headache.
Another bronchodilator used in the treatment of
COPD is theophylline, which is taken orally.
Theophylline affects many parts of the body,
including muscle tissue and the heart.  It works by
opening up the airways, increasing muscle
endurance, and decreasing muscle fatigue.  At one
time, theophylline was the most widely prescribed
COPD medication, but it has lost favor because of
side effects.  However, theophylline may have
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benefits that go beyond bronchodilation, and it is
still an important part of COPD management.
Theophylline is taken orally once or twice a day,
so it may be particularly valuable for noncompliant
patients who cannot optimally use aerosol therapy.
The dosage should be adjusted to reach a 
therapeutic serum level, so blood levels should be
monitored.  However, some patients experience side
effects even at low serum levels.  The most common
side effects seen are nausea, vomiting, headache and
insomnia.
Currently, inhaled corticosteroids are not
indicated for the treatment of COPD.  They are the
cornerstone of asthma therapy, but have a limited
role in the maintenance of lung function in patients
with COPD.  Only about 10 % of patients with
COPD show a significant improvement in lung
function when treated with corticosteroids.  The
reason is that different mediators cause inflamma-
tion in asthma and COPD.  The mediators that cause
inflammation in COPD have only limited respon-
siveness to corticosteroids, while those mediators
responsible for inflammation in asthma are 
dramatically affected by inhaled corticosteroids.
Surveys of clinicians' prescribing habits,
however, have shown little difference in the use of
inhaled corticosteroids for asthma patients and for
COPD patients.  Guidelines for the treatment of
COPD suggest that because inhaled corticosteroids
play only a minor role in the maintenance treatment
of COPD and may produce systemic side effects,
they should be reserved for patients whose
symptoms are not optimally controlled with 
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bronchodilators.  This subgroup of patients should
receive inhaled or oral corticosteroids for a trial
period.  If a significant objective clinical response 
is not achieved, corticosteroids should be discon-
tinued.  When a benefit is observed with oral 
corticosteroids, the dose should be tapered to the
lowest possible dose.  At that point, a trial of an
inhaled corticosteroid should be initiated.  The most
common side effects of inhaled corticosteroids
include upper respiratory infection, headache and
pharyngitis. 
Antibiotics may be given to patients with COPD
for acute bacterial infections of the respiratory tract,
including sinusitis, acute bronchitis and some types
of pneumonia.  Antibiotics are also used to treat
exacerbations when symptoms of infection are
present, such as fever, increased cough and sputum
changes.42
COPD patients are at high risk for respiratory
tract infections; therefore prophylaxis via 
vaccination is recommended for this population.
Vaccination can reduce the incidence and severity
of bronchial infections with which COPD morbidity
and mortality is closely associated.  Annual vaccine
against influenza, with vaccine formulation and
potency revised yearly is essential. Amantadine and
similar drugs can be used for prophylaxis during
high-risk periods for influenza for patients who
either have not been vaccinated in time or for
patients who have had prior allergic reactions to the
vaccine or are allergic to eggs.   
Although there is debate about its benefits, the
pneumococcal vaccine is also currently recom-
mended for all COPD patients.  This vaccine is not
given annually, and there is concern about the rate
of decline in immune response and immune
reactions in immunocompetent patients.43
Long term oxygen therapy (LTOT) is used to
treat patients with chronic hypoxemia (low levels of
oxygen being carried by the blood).  It can improve
survival, exercise tolerance, sleep efficiency, and
cognitive performance in these patients.  The use of
LTOT can be continuous, with activity only, or
during sleep, depending on the needs of the patient.
There are established guidelines for prescribing
oxygen for patients.  These guidelines are based on
the values of arterial blood gases or pulse oximetry
testing at rest and with activity (if tolerated by the
patient).  All prescriptions for oxygen should
include the source of oxygen (gas, liquid or concen-
trator), the method of delivery, duration of use, and
specific flow rates for rest, exercise and sleep.44
Non-pharmacological Interventions       
These include pulmonary rehabilitation services,
which may require long-term adherence by the
patient from diagnosis throughout the course of
their disease, and surgical options, which are not
widely used, but have had some beneficial
outcomes in select patients.
Pulmonary rehabilitation is a multidisciplinary
program of care that is individually tailored and
designed to optimize the COPD patient’s physical
and social performance and autonomy.
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Comprehensive pulmonary rehabilitation generally
includes exercise training (endurance and strength),
education (promoting disease awareness and 
self-management), psychosocial and behavioral
intervention (support groups and referral to 
behavioral health services), nutritional therapy and
outcome assessment.  Smoking cessation interven-
tion is an obviously important component of the
pulmonary rehabilitation process for smokers. 
Pulmonary rehabilitation is usually coordinated
by an experienced healthcare professional, such as a
registered nurse, physical therapist or respiratory
therapist.  Also involved is a multidisciplinary team
that varies between programs, but often includes
physicians, nurses, respiratory therapists, physical
therapists, occupational therapists, psychologists,
dieticians and social workers. 
Pulmonary rehabilitation results in improve-
ments in multiple outcome areas of considerable
importance to the patient, including dyspnea,
exercise ability, health status and healthcare utiliza-
tion.  These positive effects occur despite the fact
that it has a minimal effect on static pulmonary
function measurements.  This reflects the fact that
much of the morbidity from COPD results from
secondary conditions, which are often treatable if
recognized.  Examples of these treatable conditions
are cardiac deconditioning, peripheral muscle
dysfunction, and a reduction in total and lean body
mass anxiety, and poor coping skills.45
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Surgical interventions for COPD are limited to
those few selected patients who might benefit from
the procedure, are healthy enough to withstand the
trauma of the surgery, and who will be compliant
with and able to tolerate aftercare.  These surgeries
include bullectomy, lung volume reduction surgery,
and lung transplantation, which may result in
improved spirometry, lung volume, exercise
capacity, dyspnea, health-related quality of life and
possibly survival in highly selected patients.  
• Bullectomy: This is a procedure in which a large
bulla, which does not contribute to gas exchange,
is removed to alleviate local symptoms such as
hemoptysis, infection, or chest pain, and to allow
re-expansion of the compressed lung region.  It
can be done thoracoscopically.  
• Lung Volume Reduction Surgery: This is a
surgery in which parts of the lung are resected to
reduce hyperinflation.  This results in making
respiratory muscles more effective by improving
their mechanical efficiency.  This procedure also
increases the elastic recoil pressure of the lung and
thus improves expiratory flow rates.
• Lung Transplantation: This is a highly limited
procedure due to cost, availability of donor organs,
and selectivity of appropriate candidates.  There is
also considerable question about the long-term
survival benefits, although it has been shown to
increase functional capacity and improve quality
of life.46
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Exacerbations
An exacerbation of COPD is an event that
changes the natural course of the disease so that
symptoms become more severe, and a change in
management of the disease is warranted.  The
causes of exacerbations may be infectious or 
non-infectious, and in some instances, the reason
for worsening of symptoms remains unknown.
Severity of exacerbations varies, and prognosis
often depends on the stage of advancement of the
disease and the existence of comorbid conditions.
Common comorbid conditions associated with poor
prognosis in exacerbations are congestive heart
failure, coronary artery disease, diabetes mellitus,
renal and liver failure.  Most often, exacerbations
can be managed by primary care physicians on an
outpatient basis.  Corticosteroids and antibiotics 
are used widely in the management of COPD 
exacerbations.  It is essential that patients 
understand how to monitor their symptoms and
detect when there is a change, so that they can
immediately seek medical attention.
In some instances, exacerbations can be so
severe that hospitalization is required, even including
non-invasive or invasive mechanical ventilation.
There are times when a patient cannot be removed
from ventilation after an exacerbation and becomes
ventilator dependent.  Some patients who are
dependent on mechanical or assisted ventilation can
be discharged from the hospital on ventilators and
can continue to be managed at home.  This requires
coordinated support from caregivers and health
professionals, but is less costly than hospitalization
or extended care facilities, and can provide an
improved quality of life for patient and family.
When COPD patients experience an exacerba-
tion, causing them to interact with healthcare
professionals and institutions, it can be seen as an
opportunity for evaluation, education, and follow-up.
Unfortunately, approximately one third of patients
with acute exacerbations have recurrent symptoms
within 14 days, and 17% relapse and require hospi-
talization.47 Identifying those patients at risk for
relapse and providing adequate follow-up can
reduce these rates.  Efficacy of disease treatment
and management of the COPD patient with an 
exacerbation should be measured not just by
recovery from exacerbations, but also by 
exacerbation-free intervals, resource utilization, 
and improved quality of life.48


Epidemiology and Research
Objectives
1. Establish a surveillance system to accurately
track the mortality and morbidity of COPD in
Arizona, and also measure the impact on the
economy of the state.
2. Support research into COPD etiology and clinical
management, as well as healthcare policies and
outcomes particularly as the activities relate to
state issues. 
Rationale
It is essential that COPD prevalence be assessed
and monitored as a foundation for managing the
disease.  Disease surveillance is difficult and
expensive, but in regard to COPD, accurate
epidemiological data is particularly elusive.
Prevalence and morbidity data, when available,
greatly underestimate the total burden of COPD
because the diagnosis is usually delayed until it is
clinically apparent and moderately advanced. 
The term Chronic Obstructive Pulmonary
Disease is imprecise and variably defined, and is not
often used in health surveys.  The diseases under
Objec t i ves
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this umbrella term may or may not include asthma,
and chronic bronchitis is often confused with acute
bronchitis.  Other chronic obstructive lung diseases
such as obliterative bronchiolitis and cystic fibrosis
are excluded since they have known etiology or
specific pathology.49 Other nomenclature for COPD
as defined in this paper include Chronic Obstructive
Lung Disease, or Chronic Lower Respiratory
Disease, which could include diseases other than
emphysema and chronic bronchitis.  
Mortality data for COPD is also underestimated
because it is more likely to be cited as a contribu-
tory rather than as an underlying cause of death if it
is cited at all.  This is also a problem with hospital-
ization data.50
Research progress in the field of COPD has
been slow and mostly focused on the association of
COPD with cigarette smoking.  There has not yet
been significant research leading to a reduction in
COPD prevalence or morbidity, to the development
of any therapy proven to modify the disease process
itself, or to an adequate understanding of how risk
factors other than cigarette smoking may contribute
to COPD.  
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Understanding why only certain smokers
develop COPD not only illuminates the mechanisms
of the development of the disease, but also might
allow for the targeting of intensive smoking 
interventions to individuals at highest risk while
enhancing the effectiveness of these interventions.
There are also variations in the rate of decline in
lung function among individuals with COPD that
suggests intrinsic or environmental factors 
influencing disease course, which may differ from
those determining susceptibility to disease.
Recommended objectives for future research
include description of the disease process, disease
pathogenesis, advanced therapeutic modalities and
clinical studies to validate or revise current clinical
practices.51
Objective
1. Establish a surveillance system to accurately
track the mortality and morbidity of COPD in
Arizona, and also measure the impact on the
economy of the state.
Strategies
• Develop surveys to collect data not available
through existing data sources.
• Use existing and new data sources to assess (by
demographic, geographic, and socioeconomic
variables):
a. COPD disease severity (e.g. hospitalization
rates, mortality rates, emergency department
visit rates).
b. COPD management and treatment patterns
(e.g. prescription utilization patterns).
c. Cost of COPD (e.g. direct and indirect costs
including AHCCCS, medical care billing and
pharmacy costs).
d. Prevalence of exacerbations.
e. Disparities in access to healthcare for COPD
in target populations.
f. Quality of life for people with COPD and
their families.
• Establish a standardized case definition of
COPD, and establish criteria for the measurement
of COPD morbidity and mortality.
• Collect accurate, timely data on prevalence,
morbidity, mortality, and cost statistics for
COPD.
• Create an infrastructure for emergency 
department and hospitalization data to be
obtained from all medical facilities statewide
including federal and tribal and Bureau of Indian
Affairs institutions.
• Collect data and do analysis on the effect of
COPD on work ability, efficiency, and job
choice, as well as the effect of occupational
exposures on COPD risk.
• Ensure adequate resources to develop and/or
maintain new and/or existing surveillance
systems.
• Disseminate reports based on acquired data to
community stakeholders.
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Objective
2. Support research into COPD etiology and clinical
management, as well as healthcare policies and
outcomes particularly as the activities relate to
state issues. 
Strategies
• Improve data sources to increase understanding
of COPD risk factors and evaluate effectiveness
of interventions.
• Encourage basic and clinical research to develop
new and effective disease modifying therapies
that will decrease the loss of lung function,
restore lung function, and lengthen lifespan.
• Identify intermediate end-points and biomarkers
for the effective and efficient translation of basic
research findings to clinically relevant outcomes.
• Increase research related to occupational and
environmental causes and contributors to COPD.
• Foster research that addresses the risk and
resiliency of smokers in the development of
COPD and the variation in susceptibility to
COPD and disease progression that distinguishes
the 10 to 20% of smokers of one pack per day 
or more who eventually develop clinically 
significant airflow limitation from other tobacco
smokers who never develop airway dysfunction.
• Encourage research funding to develop and
evaluate the role of chronic disease management
programs for COPD.
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• Perform research studies to determine the
necessary elements and best timing for
pulmonary rehabilitation, including cost/benefit
analyses.
• Increase participation in clinical trials through
education of patients.
Treatment and
Management
Objectives
3. Improve early detection and diagnosis of COPD.
4. Promote better care for patients with COPD in
Arizona according to established guidelines.
5. Educate healthcare providers to manage patients
with COPD to increase longevity and quality of
life and reduce exacerbations of the disease.
6. Establish physician-patient partnerships through
education and management.
7. Improve access to pulmonary rehabilitation
programs for Arizonans with COPD in order to
prevent and forestall premature morbidity and
mortality.
Rationale 
Currently in the U.S., mortality due to chronic
obstructive pulmonary disease is ranked number
four and is projected to rise to number three by
2020.  The number of patients with physician
diagnosed COPD is estimated at 10 million, the
number of people with abnormal lung function is
estimated at 24 million.  The underdiagnosis of lung
disease in the U.S. may approach 14 million.52
38
Healthy People 2010 describes the following
opportunities to help meet its objectives for
improving health for individuals with COPD:
“Primary care physicians are in a key position to
provide optimal care to patients with COPD and to
provide counseling during clinical or health center
visits to patients who smoke.  Effective tests are
available to screen patients for COPD, and primary
care physicians need to be trained in the latest
methods to detect and treat the disease.”
Since COPD can remain asymptomatic for 20 to
30 years before clinical symptoms appear, and by
the time it is diagnosed, 75% of lung function has
been lost, it is essential that early diagnosis and
intervention occur in those people at risk for COPD.
Early diagnosis coupled with smoking cessation can
improve lung function and retard the rate of decline
and deterioration of quality of life.  Preliminary
studies have indicated that knowledge of abnormal
lung function can be a powerful motivator in
smoking cessation and that smokers who are tested
who have normal lung function may be motivated
by relief that smoking has not yet damaged their
lungs.  Not only COPD, but also risk of lung cancer,
heart attack and stroke is predicted by abnormal
spirometry results.  The spirometer is a tool for all
four of these most common causes of death in the
U.S. and the world.  The National Lung Health
Education Program is promoting patients to 
“Test Your Lungs, Know Your Numbers,” so that
spirometric values are as well known as blood type,
blood pressure and cholesterol levels, and they 
are working to educate providers and demystify
spirometry, to foster utilization by healthcare
professionals.53
Objective
3. Improve early detection and diagnosis of COPD.
Strategies
• Spirometry capability should be available to all
healthcare professionals.
• Develop a practical and feasible list of indica-
tions for spirometry and an easily understandable
algorithm for interpretation and action.
• Encourage primary care providers to perform an
office spirometry test for all patients over 45
years old who report smoking tobacco, or anyone
of any age who has one of the cardinal symptoms
of COPD: chronic cough, excess mucus (sputum)
production, dyspnea on mild exertion out of
proportion to age, or wheezing.
• Develop a consensus for severity assessment
criteria, and promote consistent utilization of
criteria by healthcare providers.
Objective
4. Promote better care for patients with COPD in
Arizona according to established guidelines.
Strategies
• Establish a community standard for COPD
including consensus on clinical guidelines to be
adopted (i.e. American Thoracic Society,
“Standards for the Diagnosis and Care of Patients
with Chronic Obstructive Pulmonary Disease”).
• Assess current healthcare provider knowledge of
established standard clinical guidelines.

40
O b j e c t i v e s
Arizona Comprehensive Lung Disease Control Plan
• Set measurable clinical standards based on 
scientifically valid management guidelines.
Objective
5. Educate healthcare providers to manage patients
with COPD to increase longevity and quality of
life and reduce exacerbations of the disease.
Strategies
• Implement physician education programs that
impact behavior change such as reminder
systems, standing orders, clinical pathways or
protocols, opinion leaders and physician
champions, as well as self-monitoring and
feedback. 
• Conduct provider education utilizing interactive
techniques on diagnosis and management of
COPD.
• Create an incentive program to motivate 
healthcare providers to participate in educational
sessions. Develop interdisciplinary models of
COPD care.
• Work with healthcare providers to develop
models for chronic disease management that are
applicable to COPD.
• Develop or adopt a COPD education program to
certify health educators in Arizona.
• Partner with non-profit agencies and community
organizations to facilitate provider education.
• Promote the use of COPD management plans as
part of comprehensive COPD education
programs for providers.
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Objective
6. Establish physician-patient partnerships through
education and management.
Strategies
• Encourage providers to promote healthy living
practices to patients such as tobacco cessation,
good nutrition, physical activities and regular
vaccinations against influenza and pneumonia.
• Create incentives for healthcare professionals to
counsel their patients in healthy lifestyle choices,
and COPD self-management.
• Educate providers to develop and utilize COPD
disease management plans to enable their
patients to avoid exacerbations of their 
disease and/or minimize the severity of these
exacerbations.
• Coordinate efforts with health plans, medical
providers, government and non-government
agencies, families, and other stakeholders to
promote, develop, use and disseminate COPD
disease management plans for all patients 
with COPD.
Objective
7. Improve access to pulmonary rehabilitation
programs for Arizonans with COPD in order to
prevent and forestall premature morbidity and
mortality.
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Strategies
• Increase awareness of the effectiveness of
pulmonary rehabilitation among patients with
COPD, physicians (both primary care and
specialists), and policy makers, including
AHCCCS (Arizona Healthcare Cost 
Containment System).
• Address issue of adequate reimbursement for
pulmonary rehabilitation services.
Patient Education and
Quality of Life Issues
Objectives
8. Improve self-management knowledge and
behavior in people with COPD, their families and
other caregivers.
9. Provide social support for patients, families, and
caregivers impacted by COPD.
Rationale
Education about COPD and methods for treatment
and management are critical in enabling patients to
understand the disease process and provide them
with the knowledge they need to make informed
decisions.  An effective disease management
program that balances nutrition, exercise and
behavior modification can help patients cope with
symptoms, avoid exacerbations and comorbid
conditions and focus on a positive program to
prolong quality of life, keeping them active and
productive for as long as possible.  The families of
COPD patients absorb a tremendous burden, 
particularly in the later stages of the disease, when
mild exertion is difficult and the patient ceases to be
ambulatory.  Support and education for the patient
and family can improve quality of life, but also
reduces the direct and indirect costs to our society.
Objective
8. Improve self-management knowledge and
behavior in people with COPD, their families
and other caregivers.
Strategies
• Develop or promote models for chronic disease
management applicable to COPD.
• Institutionalize the use of COPD disease 
management plans modeled after asthma
management plans.
• Encourage improved patient/provider 
relationships to enhance COPD education and
self-management skills.
• Develop or identify a clearinghouse of COPD
related information and resources which are
available on the Internet.
• Work with community organizations to make
COPD education materials available statewide.
Objective
9. Provide social support for patients, families, and
caregivers impacted by COPD.
Strategies
• Establish and sustain COPD support groups for
patients, families and caregivers.
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• Evaluate home care and monitoring in relation to
utilization of healthcare resources including
physician offices, emergency departments,
skilled nursing facilities, and acute care facilities.
• Include COPD management in workplace
wellness and disease management programs.
Prevention
Objectives
10. Promote healthy living practices, which provide
the most effective method of preventing COPD
(tobacco abstinence, periodic health checks,
avoidance of unhealthy work environments).
11. Reduce exposure to environmental and occupa-
tional risk factors to prevent the onset and
progression of COPD.
Rationale
Since 80 to 90% of COPD cases occur in
tobacco users, obviously abstinence from tobacco
use would vastly decrease morbidity and mortality
for the disease.  In addition, early detection of
airway hyperreactivity by healthcare providers
during routine health checks can be a tool in 
motivating tobacco users to quit, thereby preventing
the development of COPD and the subsequent
progression of the disease.
Tobacco addiction is complex and the fact that
the devastating health effects caused by tobacco use
and secondhand smoke exposure on average take
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decades to appear greatly contributes to the limited
perceived risk of tobacco use.  A long-term compre-
hensive tobacco control program which focuses on
preventing the initiation of tobacco use among
youth and young adults, promoting quitting, and
reducing exposure to secondhand smoke is essential
to reduce the disability and death related to COPD.
Environmental exposure to certain inhalants 
is another cause of COPD.  Management of 
controllable exposure such as workplace regulations
of occupational inhalants and policies protecting the
public from environmental tobacco smoke can
reduce potential risk.  When environmental
exposure is coupled with tobacco use, the total load
of inhaled irritants increases the risk of developing
the disease exponentially.
Objective
10. Promote healthy living practices, which provide
the most effective method of preventing COPD
(tobacco abstinence, periodic health checks,
avoidance of unhealthy work environments).
Strategies
• Encourage campaigns to emphasize the impact 
of smoking cessation.
• Develop creative approaches to alert young
people to the potential of COPD and its causes,
especially tobacco use and secondhand smoke.
• Increase resources devoted to COPD prevention
in the workplace, targeting interventions, 
and evaluating the effectiveness of those 
interventions.
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• Encourage or require third party payers to
support treatments for smoking cessation as a
component of COPD treatment.
Objective
11. Reduce exposure to environmental and 
occupational risk factors to prevent the onset
and progression of COPD.
Strategies
• Partner with state and federal regulatory agencies
to manage environmental and occupational risk
factors.
• Educate patients and caregivers about those 
environmental and occupational inhalants that
exacerbate their disease and the avoidance of
these agents.
• Promote public awareness of environmental
factors that cause and contribute to COPD.
• Disseminate educational materials on 
occupational risk factors and triggers to
employers, employees, healthcare providers and
health insurance plans.
• Promote clean indoor air quality management
plans for all public buildings.
• Promote awareness of the effects of secondhand
smoke on COPD patients.
Disparity
Objective
12. Identify and eliminate disparities in COPD
prevention, diagnosis, and management
throughout the state.
Rationale
The definition of a disparate population group
in relationship to COPD encompasses those at
highest risk to develop COPD, as well as those 
with COPD who do not have ready access to
diagnosis, treatment and management, thereby
causing them to bear a disproportionate burden of
morbidity and mortality.  Since we have established
that the incidence of COPD is highly related to
tobacco use, there is value in defining those groups
at highest risk for COPD similarly to those at
highest risk for tobacco related health disparities.
Therefore, the ADHS/TEPP strategic plan 
identification of populations at highest risk for
tobacco related health disparities is useful as stated:
“Disparities (i.e., measurable differences) derive
from ingrained patterns of resource allocation (e.g.,
services, funding, staffing, equipment, community
support, etc.) and prioritization that contribute to
modes of inequity and social injustice.  Among the
various Arizona communities, tobacco-related
disparities may be characterized by race (a class or
kind of people unified by community of interests,
habits, or characteristics – African American,
Asian, Caucasian, Hispanic), ethnicity (of or
relating to large groups of people classed according
to common racial, national, tribal, religious,
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linguistic, or cultural origin or background –
African American, specific to Asian region, 
multi-Latin American Descent, multi-European
Descent), gender (male, female, possibly 
transgender), age, income/class (what one makes
does not always reflect community status), health
status, education, sexual orientation, or geographic
location, among others.” 
As discussed previously in the plan, there is
evidence that the risk of developing COPD is
inversely related to socioeconomic status.  This
tracks the documented trend of prevalence rates of
tobacco use, which is also indirectly related to
socioeconomic status.  The relationship between
social position and respiratory disease may also be
attributed to housing conditions, poor nutrition,
exposure to occupational pollutants, and childhood
exposure to indoor air pollution.
Arizonans of lower socioeconomic status are
least likely to have access to early detection of and
intervention with COPD and tend to have erratic
relationships with healthcare providers, making
disease management and follow-up inconsistent if it
is available at all.  They also are least likely to take
advantage of state funded tobacco cessation
programs.  
Identifying differences in how racial and cultural
groups in our state view and interact with healthcare
systems will also be important in establishing
programs and methods to influence members of
these groups who are at risk or afflicted with
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chronic diseases.  Although currently COPD 
prevalence is greatest among the white population,
the large numbers of non-whites who are at risk and
who are afflicted with lung disease, as well as the
many who may be undiagnosed, make this essential
in planning interventions.
Strategies
• Identify specific populations with increased rates
of COPD and/or with limited access to COPD
resources.
• Explore constructs contributing to the burden of
COPD in identified disparate populations.
• Collaborate with community partners to identify
and promote available COPD-related resources
and education to rural and border communities.
• Develop, promote and disseminate COPD-related
resources that are culturally sensitive.
• Develop, promote, and disseminate COPD-related
resources that meet the needs of all Arizona
residents taking into account socioeconomic
status, race, education level, language and age.
• Working in conjunction with the Arizona
Healthcare Cost Containment System, develop a
system to aid uninsured residents with COPD to
obtain health insurance coverage.
• Identify emergency assistance programs and
organizations providing free or discounted
services, medications, and/or medical equipment
statewide.
• Assist healthcare providers and community
healthcare organizations to provide COPD
education to all patients diagnosed in Arizona.  
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Collaborative Efforts
Objective
13. Foster communication, collaboration and
networking opportunities among patients, 
caregivers, healthcare professionals, public
health officials, and other stakeholders.
Rationale
Partnerships are essential in any successful
disease control program.  For COPD, few 
established coalitions and workgroups exist.  It is
essential that these be created statewide to begin to
address the seriousness of COPD as a public health
issue.  Collaborative efforts among medical organi-
zations, government agencies, patient groups, and
policy makers can provide a concerted effort to
reduce the prevalence and mortality of the disease.
By sustaining and expanding a strong network,
stakeholders can promote unified, consistent
messages to raise awareness of COPD.  
By bringing together healthcare professionals,
patient organizations, governmental agencies, and
other stakeholders, efforts can be made to define
barriers, create and implement programs for 
prevention and early detection, promote better care
for patients, reach undiagnosed patients with 
information, and improve the quality of life for
those impacted by the disease. 
A well-established coalition can also stimulate
scientific research to better understand COPD, seek
new treatments for the disease, as well as prevention
strategies.  There also would be opportunities to
define and evaluate programmatic best practices,
promote established clinical guidelines, and create 
a platform for community advocacy and the 
mobilization and coordination of efforts to combat
the disease. 
Strategies
• Foster the establishment of community-based
healthcare coalitions for COPD, including the
participation of physicians and other healthcare
professionals.
• Develop public-private partnerships with 
organizations and government agencies that
include, or could be expanded to include,
projects related to COPD.
• Bring together COPD stakeholders to continually
refine, alter, promote and monitor the implemen-
tation of the COPD state plan.
Advocacy
Objective
14. Advocate and support policies to reduce the
prevalence of tobacco use and secondhand
smoke exposure among Arizonans.
Rationale
Policies that support and promote tobacco 
abstinence and clean air quality ordinances are
important in the overall reduction of COPD
morbidity and improvement of quality of life of
persons with the disease.  Increased awareness of
COPD as an important health problem by decision
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makers can set the stage for such measures.  The
relationship between tobacco use and the incidence
of COPD justifies public policy intervention due to
the high direct medical costs and indirect disability
costs associated with the disease.
Voluntary worksite policies and local ordinances
promoting smoke-free environments have spurred
interest in a statewide law that would protect all
Arizonans from the dangers of environmental
tobacco smoke while stressing importance of
tobacco abstinence.  Additionally, providing a
consistent minimal level regulation for smoking in
public places would alleviate confusion and 
competition among neighboring communities.  
Strategies
• Educate policy makers about the burden of
COPD in Arizona and the risk relationship of
tobacco use and secondhand smoke exposure.
• Public policies that promote clean indoor air
quality.
• Statewide smoke-free initiative to prohibit
smoking in all enclosed public places.
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Public Awareness
Objective
15. Increase awareness of the medical community,
public health officials and the general public
that COPD is a serious public health problem in
Arizona.
Rationale
COPD has generally been overlooked by the
public and health community, especially in 
relationship to its significant impact on mortality
and morbidity worldwide.  Some of the reasons for
this may be incomplete information about the
disease and its prevalence.  It is also a disease that
remains undetected until it is moderately advanced,
its symptoms being attributed to aging or poor
physical conditioning, with a long drawn out course
towards decline and death as compared to more
dramatic and sudden life-threatening illnesses.  The
fact that smoking tobacco causes 80 to 90% of
COPD cases has caused COPD to be viewed as 
self-inflicted, and thereby less important than other
chronic diseases, especially in regard to resources
allocated to provide surveillance, conduct research,
and improve lifestyle for patients and families.  
Difficulties in determining the human and
economic burden of COPD have previously been
discussed within this plan, as well as confusion over
the definition of the disease.  Another challenge to
positive patient outcomes is the prevalence of later
stage diagnosis.
In order to raise awareness of COPD, a 
consistent, unified message needs to be developed
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and promoted through educational programs,
workshops, and special events.  The increasing
burden of COPD will not be arrested until
knowledge and public awareness of the disease is
promoted, thereby increasing the demand for
accurate surveillance and improved public health
interventions.  In order to do this, committed 
organizations and individuals must be brought
together to exchange information and plan 
mobilization to raise the profile of this forgotten
disease and bring attention to these critical issues.  
Strategies
• Develop a COPD awareness campaign with a
clear, consistent message about COPD, tailored
to different constituencies.
• Target the awareness campaign to a variety of
groups, including health professionals, decision
makers, providers, payers, lay public, and
patients.
• Promote awareness of occupational and environ-
mental conditions that present risk factors for the
development and exacerbation of COPD cases. 
Future Directions
The ultimate goal of creating a comprehensive
COPD disease control plan should be to coordinate
existing services and available resources, identify
gaps in services, and provide a guide for future
endeavors.  In order to achieve this goal, future
steps for this comprehensive COPD disease control
plan for the State of Arizona should include 
stakeholder participation in assessing and modifying
the plan as workgroups see fit.  Stakeholders may
include among others, medical and public health
professionals, patients and caregivers, employers,
health insurance providers, and representatives from
the AHCCCS program.  This comprehensive plan is
a framework, and in order to refine and reach
toward implementation, a formal collaboration
across multiple organizations and disciplines needs
to be formed to set priorities of action, mobilize
support to implement priorities, and put in place 
an evaluation system to monitor progress and 
periodically reassess priorities.  In addition, the 
plan should be updated and revised on a continuous
basis to ensure the plan is addressing relevant issues
and meeting the needs of persons with COPD 
in Arizona.
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